tsp1

SLLK, Control Peptide for TSP1 Inhibitor acetate is a control peptide for LSKL.

SLLK is a control peptide for LSKL.

LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β .

LSKL TFA (H-Leu-Ser-Lys-Leu-NH2 TFA) is a LAP-TGFβ derivative and a TGF-β1 antagonist that can cross the blood-brain barrier, inhibits the binding of TSP-1 to LAP and reduces renal interstitial fibrosis and liver fibrosis, inhibits subarachnoid fibrosis by inhibiting TSP-1-mediated TGF-β1 activity, prevents the occurrence of chronic hydrocephalus and improves long-term neurocognitive deficits after subarachnoid hemorrhage.

SLLK, the control peptide for the TSP1 inhibitor, serves as the counterpart to LSKL.

SLLK, Control Peptide for TSP1 Inhibitor (TFA) is a control peptide for LSKL, which is a Thrombospondin (TSP-1) inhibitor.

LSKL, INhibitor of Thrombospondin (TSP-1) is a TGF-β1 antagonist that inhibits the binding of TSP-1 to LAP and reduces renal interstitial fibrosis and liver fibrosis. LSKL can also inhibit subarachnoid fibrosis, prevent the occurrence of chronic hydrocephalus and improve long-term neurocognitive deficits after subarachnoid hemorrhage by inhibiting TSP-1-mediated TGF-β1 activity.

Thrombospondin-1 (TSP-1)-derived CD36 binding motif is a bioactive peptide cyclized by a disulfide bond, critical for TSP-1-CD36 interaction. Involved in cancer metastasis, tumor adhesion, and angiogenesis, this matrix-bound glycoprotein-origin peptide competitively inhibits platelet aggregation and tumor metastasis.

SRI-31277 is a TSP1-TGFβ inhibitor.